Story perspectives

Bristol Myers Squibb Hits Phase 2 Endpoint With ALC Therapy

9/9/2026

Summary

Story summary

Bristol Myers Squibb reported its arlocabtagene autoleucel therapy met the Phase 2 primary endpoint.
The trial showed statistically significant overall response rates and achieved complete responses as a key secondary endpoint.
Shares traded around $66.82–$66.85 on September 8 2026, valuing the company at $136.49 billion.
Quarterly earnings per share were $2.04, exceeding the $1.60 consensus by $0.44.
Revenue reached $12.97 billion, about 10.5% above the $11.74 billion forecast.

1 of 1

Story summary

Bristol Myers Squibb reported its arlocabtagene autoleucel therapy met the Phase 2 primary endpoint.
The trial showed statistically significant overall response rates and achieved complete responses as a key secondary endpoint.
Shares traded around $66.82–$66.85 on September 8 2026, valuing the company at $136.49 billion.
Quarterly earnings per share were $2.04, exceeding the $1.60 consensus by $0.44.
Revenue reached $12.97 billion, about 10.5% above the $11.74 billion forecast.